Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation | Synapse
September 4, 2024
Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.